IP Group
IPO · Main Market · Financial Services · mcap £627m · 72.7p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 12 Oct 26 | IP Group leads round in Matter Machine
IP Group leads £4m pre-series A funding round in AI materials discovery company Matter Machine. |
+2.5% | |
| 02 Oct 26 | IP Group completes partial realisation in ONT
IP Group sells 10m Oxford Nanopore shares for £21m, retaining 7.23% stake worth £151.5m. |
+1.2% | |
| 15 Sep 26 | Results | Half-year Results
NAV per share increased 3.2% to 113.9p; generated £68.7m cash proceeds in H1, exceeding FY25 total. |
+2.4% |
| 05 Aug 26 | Director dealing | Director/PDMR share purchases
IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and technology companies with the potential to create a better future for all, has been notified that on 4 and 5 |
+2.1% |
| 27 Jul 26 | IP Group - Response to Rule 2.8 announcement
Railpen confirms it will not make an offer for IP Group; takeover approach ends. |
−0.6% | |
| 27 Jul 26 | Rule 2.8 Announcement
Railpen confirms no intention to make offer for IP Group after months of unsuccessful negotiations. |
−0.6% | |
| 20 Jul 26 | Offer | Statement re Possible Offer
Railpen's revised offer of 61p cash plus ONT shares and CVR unanimously rejected; 7-day extension granted to improve terms. |
+0.2% |
| 17 Jul 26 | Offer | Further Statement re Possible Offer
Railpen makes improved takeover proposal for IP Group at 61p cash plus ONT shares plus Metsera CVR. |
−0.3% |
| 23 Jun 26 | Offer | Response to Possible Offer for IP Group plc
Railpen's takeover proposal for IP Group rejected by board as materially undervaluing the company. |
+0.6% |
| 22 Jun 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
+0.5% | |
| 22 Jun 26 | Offer | Statement re Possible Offer
Railpen, IP Group's 18.4% shareholder, proposes takeover at 69.7p per share including deferred value; board rejects offer. |
+0.5% |
| 16 Jun 26 | Istesso starts trial of leramistat in sarcopenia
Portfolio company Istesso begins Phase 2 trial of leramistat in sarcopenia patients. |
−0.2% | |
| 12 May 26 | Results | Enterprise reports positive results from P2 trial
Portfolio company Enterprise Therapeutics reports positive Phase 2 trial results for cystic fibrosis candidate ETD001. |
−1.1% |
| 07 May 26 | Board change | Appointment of Chair Designate
Michael Queen appointed as Non-executive Director and Chair Designate, to succeed Sir Douglas Flint at AGM on 18 June 2026. |
+2.8% |
| 21 Apr 26 | First Light announces £25m successful first close
Portfolio company First Light Fusion raises £25m in funding round led by East X Ventures and UKAEA. |
+1.4% | |
| 15 Apr 26 | Results | Annual Report
IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it has published i |
+2.1% |
| 30 Mar 26 | New climate fund launch with Australia's CEFC
IP Group launches A$150m climate fund with Australia's CEFC targeting hard-to-abate industry decarbonisation. |
+0.2% | |
| 17 Mar 26 | Results | IP Group plc 2025 Annual Results Release
NAV per share up 13% to 110.4p; Pfizer Metsera acquisition recognises £128.2m future royalty income. |
+10.7% |
| 04 Mar 26 | Portfolio company Oxa raises $103m in Series D
Portfolio company Oxa raises $103m Series D, led by National Wealth Fund and NVentures, IP Group invests $35m. |
+1.3% | |
| 11 Feb 26 | Results | Microbiotica announces positive P1b trial results
Portfolio company Microbiotica announces positive Phase 1b trial results for MB310 in ulcerative colitis. |
+0.3% |
| 14 Jan 26 | Board change | Directorate Change
Chair Sir Douglas Flint to retire at June 2026 AGM after joining Prudential board. |
−0.7% |
| 07 Jan 26 | Pulmocide announces termination of Phase 3 study
Portfolio company Pulmocide terminates Phase 3 study of opelconazole for invasive pulmonary aspergillosis. |
−3.4% | |
| 20 Nov 25 | Completion of share buyback programme
IP Group completed £20m share buyback extension, purchasing 157.97m shares at 47.5p average. |
+0.2% | |
| 17 Nov 25 | Artios completes oversubscribed $115m financing
Portfolio company Artios completes $115m Series D financing round; IP Group invests £5.5m, holding 6.8%. |
−1.3% | |
| 13 Oct 25 | Potential income from Metsera obesity drugs
Pfizer agreed to acquire Metsera for up to $7.3bn; IP Group entitled to future royalties on obesity drugs. |
+10.7% | |
| 08 Oct 25 | Portfolio co Monolith to be acquired by CoreWeave
Portfolio company Monolith acquired by Nasdaq-listed CoreWeave; IP Group holds 12.3%. |
+2.5% |
Company filings. Not investment advice.